Reply  by Jeremias, Allen et al.
Creatine Kinase-MB Elevation
Following Stent Implantation
We read with interest the study by Jeremias et al. (1) published in
the Journal. The investigators claim that creatine kinase-MB
fraction (CK-MB) elevations following stent deployment portend
an unfavorable prognosis only for patients with unsuccessful
procedures. Although this finding may be true, we have several
reservations.
The researchers do not provide the absolute number of deaths;
however, it can be indirectly inferred from the presented total
number of patients and event rates that their entire study includes
only 10 deaths among patients with an unsuccessful procedure and
about 100 more deaths in patients with successful procedures. The
main inferences are practically based on 10 deaths. Such small
numbers do not allow any meaningful modeling in CK-MB strata
or multivariate analyses.
Furthermore, the use of percentages is misleading here; for
example, the 5% death rate on patients with type 2 myocardial
infarction (MI) and unsuccessful procedure is based on a single
death, and the 9.1% death rate on patients with type 1 MI is based
on only two deaths! Even the unadjusted analyses are based on
extremely thin information. The successful procedure data are also
limited: the observed differences of 0.4% to 0.7% excess death rate
with small CK-MB elevations are certainly not statistically signif-
icant given the small number of events, but they may be clinically
important when extrapolated to the millions of patients who
undergo “successful” procedures.
Moreover, the overall one-year death rate in the study by
Jeremias et al. is only 2%, whereas it has been about 4% in other
studies evaluating peri-procedural MI (2). The same relative risk
increase would have a larger absolute magnitude in a population at
higher baseline risk of death.
We are also concerned that the details of the study protocols
and justification of data pooling as described in the study by
Jeremias et al. (1) are not fully described in the cited reference (see
reference 8 in their report). The definition of “unsuccessful”
procedure is not standardized in the published data. The definition
of Jeremias et al. comprises five different elements (stenosis, flow
grade, dissection, repeat revascularization, stent thrombosis). Each
of these may be selected with different cutoffs (e.g., stenosis 50%
or 30%; dissection D or C; Thrombolysis In Myocardial
Infarction [TIMI] flow grade 3 or other criteria). Some inves-
tigators may use only some (3,4), but not all, of these criteria, or
may add other parameters (5). In a database of 6,186 patients, it is
almost certain that definition changes can always allow identifica-
tion of a minuscule group of about 100 patients where 10 deaths
have occurred and thus support a claim that this is the high-risk
group par excellence.
Overall, such claims about high-risk groups are primarily
hypothesis-generating speculations. It is important to try to
replicate these findings in other patient cohorts using the exact
same definitions. Chances are that the greater the degree of
selection and strict data-fitting in the original investigation, the
less likely the findings are replicated elsewhere (6). Nevertheless,
given the great clinical importance of the observations made by
Jeremias et al. (1), such validation is essential.
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REPLY
We thank Dr. Ioannidis and colleagues for their interest in our
study (1), in which we hypothesized that procedure success would
have a significant effect on the reported association between
mortality and peri-procedural creatine kinase-MB fraction (CK-
MB) elevation. Dr. Ioannidis and colleagues have raised concerns
regarding insufficient numbers of patients and events to adequately
address the question, justification for pooling of the clinical trial
data, interpretation of the small absolute risk difference, and a
definition of procedure success that is not standardized in the
published data.
These same investigators have published a meta-analysis of
23,230 patients (including ACS [acute coronary syndrome] and
vein graft interventions) treated by a mixture of stent, directional
coronary atherectomy, and balloon angioplasty over a decade,
showing a one-year mortality risk of 3.5% with normal CK-MB,
rising to 5.2%, 6.3%, and 10.9% for CK-MB 1 to 3, 3 to 5, and5
times normal, respectively (2). What such meta-analyses gain in
numbers of patients and events may be lost in lack of detail about
those patients—for instance, whether the effect holds true for
stenting (as used in 90% of current interventions), and whether it
applies equally to incidental CK-MB elevations seen after other-
wise successful procedures. Our study is actually one of the largest
reports after elective stenting, with nearly 6,000 patients and over
100 death events, and includes data pooled at the patient-by-patient
level, so that it could look into the question with greater granu-
larity. The pooling of the trials was fully justified based on the
nearly identical inclusion criteria and baseline clinical and angio-
graphic characteristics (3,4). The one-year mortality was similar to
other elective stent populations (5) and was essentially flat for
normal-to-moderate level CK-MB elevations among successful
procedures, whereas mortality was over six times higher in patients
with unsuccessful procedures and any elevation in CK-MB.
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As we stated in our discussion, the 0.4% absolute difference in
mortality between patients with and without myocardial infarction
(MI) after successful intervention could still be clinically meaning-
ful. But we must reject the other criticisms of Dr. Ioannidis and
colleagues regarding the limitations of our study. The inferences
are not based on a small number of unsuccessful procedures, but on
an analysis of 5,850 patients with over 100 deaths, for which an
unsuccessful procedure was one of the most significant indepen-
dent predictors of one-year mortality. Most importantly, we are
concerned with the misinterpretation of our identification of
successful and unsuccessful procedures. We were careful to select
unsuccessful procedures using criteria on which most operators
would concur in the context of current stenting techniques. We
agree many would choose to broaden these criteria and thus further
purify the successful group. Regardless of where this line of success
is drawn, however, it is clear that the effect of CK-MB elevation
among truly successful procedures in this patient cohort would be
small to nonexistent.
We also agree that this finding is worth validating in larger
numbers of patients. Doing so will require access to databases
where the pre-procedure risk and results of successful and unsuc-
cessful procedures are clearly identified, thereby avoiding unnec-
essary panic among patients and their physicians when small
elevations in CK-MB are detected following an otherwise success-
ful procedure.
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Cardiac Rehabilitation
Following Myocardial Infarction
In an observational study Witt et al. (1) report a striking survival
advantage among patients attending cardiac rehabilitation. They
employ a rather unusual adjustment to compare patients of very
different ages, a “propensity to attend cardiac rehabilitation” rather
than the more usual inclusion of prognostic risk factors in
multivariate analyses.
Their findings are not borne out by randomized trials. In
discussion, they comment that early (small) trials may not be
generalized to contemporary practice. Too true. Pooling of all trials
undertaken since the World Health Organization European col-
laborative (but excluding ours, see the next sentence) show collec-
tively no significant effect on mortality (2). The only multicenter
trial undertaken since widespread use of thrombolysis, aspirin,
beta-blocker, angiotensin-converting enzyme inhibitor, and statin
shows no effect on mortality (3).
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REPLY
We appreciate the interest of Dr. West in our work (1). We
respectfully take issue with the statement that the use of
propensity-score methodology is unusual. Indeed, the use of
propensity score is a commonly used, well-accepted method of
statistical adjustment (2,3). It is considered by many to be
preferable to conventional regression analysis to adjust for differ-
ences in baseline characteristics and control for confounding by
indication. As in any observational study, however, we cannot rule
out residual confounding related to unmeasured characteristics.
This point, which was emphasized in our report, is important to
underscore in the interpretation of our data.
As underscored by Dr. West, and as stated in our study,
randomized controlled trials constitute the methodological gold
standard to test the effect of an intervention. Dr. West quotes one
meta-analysis of four trials (4) and one multicenter randomized
trial (4). Both of these are published only in abstract format, and
neither one provides sufficient information to interpret the find-
ings. For example, the trial inclusion criteria or components of the
rehabilitation programs may be substantially different from what is
reported in our community-based myocardial incidence cohort (1).
These differences could, in turn, explain the observed differences in
survival. More importantly, the duration of follow-up in the
randomized trial is only 12 months (5), shorter than in our
published follow-up of 6.6 years (1). Finally, the apparent age and
gender disparities in the delivery of care noted in our analysis could
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